The effects of salmeterol/fluticasone on circulating biomarker in stable chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000442

Enrollment

Unknown

Registered

2009-07-01

Start date

2008-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

B:Ipratropium/albnterol 36/206µg q.i.d (Combivent inhalation aerosol, Boehringer Ingelheim, Inc.)

A:50 µg salmeterol and 500 µg fluticasone propionate (Advair Diskus, Seretide, GlaxoSmithKline)

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Forced expiratory volume in one second (FEV1) of more than 30% of predicted with an FEV1 to forced vital capacity (FVC) ratio of less than 0.70; 2. Absence of exacerbations for at least 3 months, age >=40 years.

Exclusion criteria

Exclusion criteria: 1. Currently use oral or inhaled corticosteroid; 2. Complication with the diseases which were associated with increased CRP levels (e.g. rheumatoid arthritis, congenital heart failure, tuberculosis, or cancer).

Design outcomes

Primary

Measure	Time frame
C-reactive protein;	—

Secondary

Measure	Time frame
Fibrinogen, IL-6, and TNF-alpha;	—

Countries

China

Contacts

Public ContactKe Wang

wangke@scu.edu.cn+86 028 81812271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026